The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The guideline offers clear, concise, and actionable recommendation statements to help clinicians to incorporate recommendations into clinical practice, with the goal of improving quality of care. Each recommendation is given a rating that reflects the level of confidence that potential benefits of an intervention outweigh potential harms.

The aim of the American Psychiatric Association Practice Guideline series is to improve patient care. Guidelines provide a comprehensive synthesis of all available information relevant to the clinical topic. Practice guidelines can be vehicles for educating psychiatrists, other medical and mental health professionals, and the general public about appropriate and inappropriate treatments. The series also will identify those areas in which critical information is lacking and in which research could be expected to improve clinical decisions. The Practice Guidelines are also designed to help those charged with overseeing the utilization and reimbursement of psychiatric services to develop more scientifically based and clinically sensitive criteria.

These guidelines from NICE set out clear recommendations, based on the best available evidence, for health care professionals on how to work with and implement physical, psychological and service-level interventions for people with various mental health conditions.The book contains the full guidelines that cannot be obtained in print anywhere else. It brings together all of the evidence that led to the recommendations made, detailed explanations of the methodology behind their preparation, plus an overview of the condition covering detection, diagnosis and assessment, and the full range of treatment and care approaches. There is a worse prognosis for psychosis and schizophrenia when onset is in childhood or adolescence, and this new NICE guideline puts much-needed emphasis on early recognition and assessment of possible psychotic symptoms. For the one-third of children and young people who go on to experience severe impairment as a result of psychosis or schizophrenia the guideline also offers comprehensive advice from assessment and treatment of the first episode through to promoting recovery.This guideline reviews the evidence for recognition and management of psychosis and schizophrenia in children and young people across the care pathway, encompassing access to and delivery of services, experience of care, recognition and management of at-risk mental states, psychological and pharmacological interventions, and improving cognition and enhancing engagement with education and employment.

Alcohol use disorder (AUD) is a major public health problem in the United States. The estimated 12-month and lifetime prevalence values for AUD are 13.9% and 29.1%, respectively, with approximately half of individuals with lifetime AUD having a severe disorder. AUD and its sequelae also account for significant excess mortality and cost the United States more than $200 billion annually. Despite its high prevalence and numerous negative consequences, AUD remains undertreated. In fact, fewer than 1 in 10 individuals in the United States with a 12-month diagnosis of AUD receive any treatment. Nevertheless, effective and evidence-based interventions are available, and treatment is associated with reductions in the risk of relapse and AUD-associated mortality. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder seeks to reduce these substantial psychosocial and public health consequences of AUD for millions of affected individuals. The guideline focuses specifically on evidence-based pharmacological treatments for AUD in outpatient settings and includes additional information on assessment and treatment planning, which are an integral part of using pharmacotherapy to treat AUD. In addition to reviewing the available evidence on the use of AUD pharmacotherapy, the guideline offers clear, concise, and actionable recommendation statements, each of which is given a rating that reflects the level of confidence that potential benefits of an intervention outweigh potential harms. The guideline provides guidance on implementing these recommendations into clinical practice, with the goal of improving quality of care and treatment outcomes of AUD.

Clinical Manual for the Treatment of Schizophrenia provides a uniquely multicultural and supremely patient-centered perspective on schizophrenia's core symptoms, its psychosocial effects, and its psychopharmacological and psychotherapeutic management.

Advances in medical, biomedical and health services research have reduced the level of uncertainty in clinical practice. Clinical practice guidelines (CPGs) complement this progress by establishing standards of care backed by strong scientific evidence. CPGs are statements that include recommendations intended to optimize patient care. These statements are informed by a systematic review of evidence and an assessment of the benefits and costs of alternative care options. Clinical Practice Guidelines We Can Trust examines the current state of clinical practice guidelines and how they can be improved to enhance healthcare quality and patient outcomes. Clinical practice guidelines now are ubiquitous in our healthcare system. The Guidelines International Network (GIN) database currently lists more than 3,700 guidelines from 39 countries. Developing guidelines presents a number of challenges including lack of transparent methodological practices, difficulty reconciling conflicting guidelines, and conflicts of interest. Clinical Practice Guidelines We Can Trust explores questions surrounding the quality of CPG development processes and the establishment of standards. It proposes eight standards for developing trustworthy clinical practice guidelines emphasizing transparency; management of conflict of interest ; systematic review-guideline development intersection; establishing evidence foundations for and rating strength of guideline recommendations; articulation of recommendations; external review; and updating. Clinical Practice Guidelines We Can Trust shows how clinical practice guidelines can enhance clinician and patient decision-making by translating complex scientific research findings into recommendations for clinical practice that are relevant to the individual patient encounter, instead of implementing a one size fits all approach to patient care. This book contains information directly related to the work of the Agency for Healthcare Research and Quality (AHRQ), as well as various Congressional staff and policymakers. It is a vital resource for medical specialty societies, disease advocacy groups, health professionals, private and international organizations that develop or use clinical practice guidelines, consumers, clinicians, and payers.

Despite growing awareness in the psychiatric community of the multifaceted medical needs of the severely mentally ill, statistics show that as much as 60% of all schizophrenia patients die prematurely from nonpsychiatric medical conditions -- in part because many physicians have not yet recognized how to properly treat common diseases and illnesses within this complex patient population. Medical Illness and Schizophrenia, Second Edition, is the only clinical guide to focus exclusively on the treatment of common medical comorbidities among patients with schizophrenia. Like its best-selling predecessor, the book compiles the latest research and clinical information on integrating medical and psychiatric care for the schizophrenia patient. Twenty-eight physicians and psychiatrists, including editors Jonathan M. Meyer, M.D., and Henry A. Nasrallah, M.D., lend their expertise to this new, expanded edition. In fifteen chapters, this volume covers a wide range of common medical problems -- from metabolic and heart conditions, such as cardiovascular disease, hyperlipidemia, obesity and diabetes, to substance abuse and smoking. Each chapter concludes with "Key Clinical Points" that summarize important concepts and ensure reader retention. Additionally, the second edition includes new chapters that touch on some of the most complex clinical issues in the field of schizophrenia treatment today: Recent trends in the integration of medical and mental healthcare Behavioral treatments for weight loss in persons with schizophrenia Treatment of sexual dysfunction among persons treated for schizophrenia Health outcomes of schizophrenia treatment in children and adolescents Health outcomes of schizophrenia treatment during pregnancy and breastfeeding As the only clinical text of its kind, Medical Illness and Schizophrenia, Second Edition, is an invaluable resource for psychiatrists, nurses, healthcare professionals, and psychiatric and clinical residents. The goal of this text has always been to help clinicians recognize schizophrenia as both a brain disorder and a systemic disease with multiple manifestations that go beyond the obvious psychiatric symptoms -- and thus take a broader approach to treatment of schizophrenia. This new edition is a comprehensive, practical manual that serves as a reference for the medical management of seriously mentally ill patients across the age spectrum in both inpatient and outpatient settings.

"Schizophrenia remains the most challenging of mental disorders confronted by psychiatrists and other mental health providers. Its primary manifestations-psychotic symptoms and cognitive impairment-profoundly affect the functioning of individuals with schizophrenia. This is an updated textbook covering the current state of knowledge about schizophrenia, including its causes, nature, presentation, and treatment. Chapters are written by a roster of experts in "--